Ferraldeschi R, Pezaro C, Karavasilis V, de Bono J (2013) Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer. Annu Rev Med 64:1–13. https://doi.org/10.1146/annurev-med-121211-091605

Article  CAS  PubMed  Google Scholar 

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148. https://doi.org/10.1056/NEJMoa1209096

Article  CAS  PubMed  Google Scholar 

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197. https://doi.org/10.1056/NEJMoa1207506

Article  CAS  PubMed  Google Scholar 

Qiao Y, Choi JE, Tien JC, Simko SA, Rajendiran T, Vo JN et al (2021) Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer. Nat Cancer 2:978–993. https://doi.org/10.1038/s43018-021-00237-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pili R, Carducci M, Brown P, Hurwitz H (2014) An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. Invest New Drugs 32:1258–1268. https://doi.org/10.1007/s10637-014-0147-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu YM, Cieslik M, Lonigro RJ, Vats P, Reimers MA, Cao X et al (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173(1770–1782):e1714. https://doi.org/10.1016/j.cell.2018.04.034

Article  CAS  Google Scholar 

Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC et al (2021) Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncol 7:525–533. https://doi.org/10.1001/jamaoncol.2020.7987

Article  PubMed  Google Scholar 

Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J et al (2017) Integrative clinical genomics of metastatic cancer. Nature 548:297–303. https://doi.org/10.1038/nature23306

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cieslik M, Chugh R, Wu YM, Wu M, Brennan C, Lonigro R et al (2015) The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Res 25:1372–1381. https://doi.org/10.1101/gr.189621.115

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng SK, Dietrich MS, Dilts DM (2011) Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials. Clin Cancer Res 17:1947–1955. https://doi.org/10.1158/1078-0432.CCR-10-1730

Article  PubMed  PubMed Central  Google Scholar 

Team RC (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/

Schutz FA, Je Y, Richards CJ, Choueiri TK (2012) Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 30:871–877. https://doi.org/10.1200/JCO.2011.37.1195

Article  CAS  PubMed  Google Scholar 

Groarke JD, Cheng S, Moslehi J (2013) Cancer-drug discovery and cardiovascular surveillance. N Engl J Med 369:1779–1781. https://doi.org/10.1056/NEJMp1313140

Article  CAS  PubMed  Google Scholar 

Shah RR, Morganroth J, Shah DR (2013) Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 36:295–316. https://doi.org/10.1007/s40264-013-0047-5

Article  CAS  PubMed  Google Scholar 

Shyam Sunder S, Sharma UC, Pokharel S (2023) Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther 8:262. https://doi.org/10.1038/s41392-023-01469-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teo YL, Ho HK, Chan A (2013) Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev 39:199–206. https://doi.org/10.1016/j.ctrv.2012.09.004

Article  CAS  PubMed  Google Scholar 

Sartor O, George D, Tombal B, Agarwal N, Higano CS, Sternberg CN et al (2022) Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future Oncol 18:35–45. https://doi.org/10.2217/fon-2021-0886

Article  CAS  PubMed  Google Scholar 

Sridhar SS, Joshua AM, Gregg R, Booth CM, Murray N, Golubovic J et al (2015) A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 13:124–129. https://doi.org/10.1016/j.clgc.2014.06.001

Article  PubMed  Google Scholar 

Meadows KL and Hurwitz HI (2012) Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2. https://doi.org/10.1101/cshperspect.a006577

Ojemuyiwa MA, Madan RA, Dahut WL (2014) Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development. Expert Opin Emerg Drugs 19:459–470. https://doi.org/10.1517/14728214.2014.969239

Article  CAS  PubMed  Google Scholar